A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer Clinical Trial

Official title:

A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00759785
• Other study ID #: 0646-013
• Secondary ID: MK-0646-0132008-
• Status: Completed
• Phase: Phase 1
• Start date: September 30, 2008
• Est. completion date: February 17, 2010

Study information

• Verified date: July 2018
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to evaluate the response of growth factor signatures (GFS) to a single dose of dalotuzumab in participants with triple negative (TN) or estrogen receptor (ER)-positive luminal B breast cancer. The primary hypothesis is that dalotuzumab will induce a decrease in the GFS in at least 40% of participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 17, 2010
• Est. primary completion date: February 17, 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant has operable stage I-IIIa breast cancer of the following subtypes: (1) estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; (2) ER-positive tumor meeting one of the following criteria: histologic grade 3; histologic grade 2 and PR-negative; histologic grade 2 and Ki67 antigen =10%. Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam

• Participant is female and =18 years of age

Exclusion Criteria:

• Participant is pregnant, breastfeeding or planning to become pregnant while in the study

• Participant has received prior chemotherapy, biological therapy or radiation

• Participant has participated in a clinical trial in the last 30 days

• Participant has a history of drug or alcohol abuse in the last year

• Participant is human immunodeficiency virus (HIV) positive. Patient has a history of Hepatitis B or C

• Participant has poorly controlled diabetes mellitus

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• dalotuzumab (MK0646)
Single intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Demonstrating a Decrease in the Growth Factor Signature (GFS)	GFS was measured by microarray analysis of the entire 101 gene signature expression. The GFS is quantified as the change in gene expression between two separate samples collected from the same participant. A log (base 10) ratio of expression in the post-dose sample was generated relative to the reference in both the Up and DOWN arms of the gene signature. A log ratio value of zero indicated no change in the expression between the two samples. GFS was calculated as the mean log ratio of genes in the UP arm minus mean log ratio of genes in the Down arm. GFS was compared for paired samples (pre-dose and post-dose) by a T-statistic calculated as the GFS divided by its standard error. Responders to therapy had a T-statistic that was smaller than the threshold 1st percentile of student's T-distribution and were counted as having a decrease in GFS.	Up to 12 Days Post-dose
Secondary	Percentage of IGF1R Positive Participants With a Decrease in GFS by Cohort	Insulin-like Growth Factor Receptor Type 1 (IGF1R) expression was measured in pre-dose biopsy samples using an immunohistochemistry assay to establish baseline IGF1R positivity. Biopsy samples were considered IGF1R positive if at least 10% of tumor cells stain with intensity 1+ or greater based on staining criteria of very weak (+/-); weak (1+); moderate (2+); or strong (3+). GFS response was correlated with IGF1R expression for ER-positive luminal B and triple negative cohorts.	Up to 12 Days Post-dose
Secondary	Percentage of IGF1R Negative Participants With a Decrease in GFS by Cohort	Biopsy samples were considered IGF1R negative if less than 10% of tumor cells stain. GFS response was correlated with IGF1R expression for ER-positive luminal B and triple negative cohorts.	Up to 12 Days Post-dose
Secondary	Change From Baseline in IGF1R Membrane H-Score After a Single Dose of Dalotuzumab	IGF1R expression was measured in pre and post-dose biopsy samples using an immunohistochemistry assay. Results were expressed as an IGF1R membrane H-score. The H-score was calculated from the percentage of cells staining very weak (+/-); weak (1+); moderate (2+); or strong (3+) and obtained by the formula: (3 x percentage of strongly staining nuclei) + (2 x percentage of moderately staining nuclei) + (1 x percentage of weakly staining nuclei) + (0.5 x percentage of weakly staining nuclei). The H-score ranges from 0 to 300; with a score of 0 representing the absence of IGF1R expression and an H-score of 300 representing maximum IGF1R expression. A decrease in IGF1R membrane H-score was an indication of target engagement by dalotuzumab. A larger decrease in H-score correlated with a greater target engagement	Baseline and Up to 12 Days